الإحصائيات الأساسية
| LEI | 549300KN62PPGHBVXB46 |
| CIK | 1077183 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeoGenomics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 NEOGENOMICS, INC. |
|
| July 29, 2025 |
Exhibit 99.1 NeoGenomics Reports Second Quarter 2025 Results Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance Fort Myers, Florida (July 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quar |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| July 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2025 NEOGENOMICS, INC. |
|
| June 24, 2025 |
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors Exhibit 99.1 NeoGenomics Appoints Dr. Marjorie Green to Board of Directors FORT MYERS, Fla., June 24, 2025—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2025 NEOGENOMICS, INC. |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No. |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 NEOGENOMICS, INC. |
|
| April 29, 2025 |
, 2025, between NeoGenomics Inc. and Melody Harris Exhibit 10.6 Dear Melody: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end, effective as of June 1, 2025, (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your separation from employment and to outline your continuing obligations to the Company, including the restrictive covenants con |
|
| April 29, 2025 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Alicia Olivo (the “Executive”) and is effective as of January 1, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement b |
|
| April 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2025 NEOGENOMICS, INC. |
|
| April 29, 2025 |
NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million Exhibit 99.1 NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compar |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| April 29, 2025 |
Employment Agreement, executed August 10, 2022, by and between NeoGenomics, Inc. and Alicia Olivo Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of August 10, 2022 by and between NeoGenomics, Inc. (the “Company”) and Alicia Olivo (the “Executive”). WHEREAS, the Executive and the Company entered into a certain letter agreement dated May 11, 2022 (the “Previous Letter Agreement”) memorializing the terms and conditions |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 8, 2025 |
Amendment to the Amended and Restated Bylaws of NeoGenomics, Inc. AMENDMENT TO AMENDED AND RESTATED BYLAWS OF NEOGENOMICS, INC., a Nevada corporation April 4, 2025 The Amended and Restated Bylaws of NeoGenomics, Inc. are amended by inserting the following as Section 1.11. Section 1.11. Nominations for Directors. (a)Nominations for the election of directors may be made by the Board or by any Nominating Person (as defined herein) who (i) is entitled to vote for th |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2025 NEOGENOMICS, INC. |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 8, 2025 |
ANNUAL REPORT 2024 Corporate Officers Tony Zook Chief Executive Officer Beth Eastland Senior Vice President, Enterprise Sales Hutan Hashemi Chief Compliance Officer Andrew Lukowiak Chief Innovation Officer Nate Montgomery, MD, PhD Vice President, Medical Services and Medical Director, Durham, North Carolina Ali Olivo Executive Vice President, General Counsel and Business Development Gary Passman C |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| March 31, 2025 |
Employment Agreement effective April 1, 2025, by and between NeoGenomics, Inc. and Anthony Zook. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 1, 2025, by and between NeoGenomics, Inc. |
|
| March 19, 2025 |
March 18, 2025 NeoGenomics Appoints Warren Stone as President & Chief Operating Officer Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2025 NEOGENOMICS, INC. |
|
| March 18, 2025 |
March 18, 2025 NeoGenomics Appoints Warren Stone as President & Chief Operating Officer Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2025 NEOGENOMICS, INC. |
|
| February 18, 2025 |
NeoGenomics, Inc. Insider Trading Policy Exhibit 19.1 NEOGENOMICS, INC. INSIDER TRADING POLICY Revised February 12, 2025 A. INTRODUCTION NeoGenomics, Inc. (the “Company”) recognizes that its directors, officers, and other employees may invest from time to time in the common stock of the Company. The Company’s Board of Directors (the “Board”) adopted this policy to promote compliance with applicable securities laws that prohibit persons w |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 18, 2025 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Inivata Limited, a UK limited company NeoGenomics Bioinformatics, Inc., a Florida corporation NeoGenomics Europe, SA, a Swiss société anonyme NeoGenomics Laboratories, Inc., a Florida corporation NeoGenomics Singapore, Pte. Ltd., a Singapore private limited company Suzhou NeoGenomics Pharmaceutical Research Co., Limited, a Suzhou, China corporation Tr |
|
| February 18, 2025 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2024 Results Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth Fort Myers, Florida, (February 18, 2025) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended Dece |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2025 NEOGENOMICS, INC. |
|
| January 15, 2025 |
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - Long-Range Plan reflects 12-13% revenue growth annually - Presentation and webcast at 43rd Annual J. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 NEOGENOMICS, INC. |
|
| January 10, 2025 |
Special Advisor Agreement between NeoGenomics, Inc. and Christopher Smith, effective April 1, 2025. Exhibit 10.2 Special Advisor Agreement This special advisor agreement (the “Agreement”), effective April 1, 2025 (“Effective Date”) by and between Christopher Smith (“Advisor”), an individual whose address is 17409 Via Lugano Court, Miramar Lakes, Florida 33913 and NeoGenomics Laboratories, Inc., a Florida corporation with its principal office located at 9490 NeoGenomics Way, Fort Myers, FL 33912 |
|
| January 10, 2025 |
Letter Agreement between NeoGenomics, Inc. and Christopher Smith, dated January 8, 2025 Exhibit 10.1 January 8, 2025 Christopher Smith Dear Chris: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end as a result of your retirement, effective as of April 1, 2025 (the “Retirement Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2025 NEOGENOMICS, INC. |
|
| January 10, 2025 |
NeoGenomics Announces Chief Executive Officer Succession Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance FT. |
|
| November 5, 2024 |
NeoGenomics, Inc. Code of Business Conduct and Ethics Exhibit 14.1 NeoGenomics Code of Business Conduct and Ethics Living Our Values Table of Contents INTRODUCTION 2 DECISION MAKING USING THE CODE 2 OUR RESPONSIBILITIES UNDER THE CODE 2 OUR VALUES 3 OUR RELATIONSHIPS WITH COLLEAGUES 3 OUR RELATIONSHIP WITH CUSTOMERS AND BUSINESS PARTNERS 4 OUR OBLIGATIONS TO THE COMPANY 5 OUR FINANCIAL OPERATIONS AND RESPONSIBILITIES 7 OUR RELATIONSHIP WITH THE REGUL |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2024 NEOGENOMICS, INC. |
|
| November 5, 2024 |
Exhibit 99.1 NeoGenomics Reports Third Quarter 2024 Results Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million Fort Myers, Florida (November 5, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| July 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2024 NEOGENOMICS, INC. |
|
| July 29, 2024 |
Exhibit 99.1 NeoGenomics Reports Second Quarter 2024 Results Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million Fort Myers, Florida (July 29, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended Ju |
|
| June 13, 2024 |
As filed with the Securities and Exchange Commission on June 13, 2024 As filed with the Securities and Exchange Commission on June 13, 2024 Registration No. |
|
| June 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2024 NEOGENOMICS, INC. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| April 30, 2024 |
NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights •Consolidated revenue increased |
|
| April 30, 2024 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Second Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”) and is effective as of April 29, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the E |
|
| April 30, 2024 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Warren Stone (the “Executive”) and is effective as of April 29, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement by |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 NEOGENOMICS, INC. |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2024 NEOGENOMICS, INC. |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 26, 2024 |
Form of PSU Agreement under the NeoGenomics, Inc. 2023 Equity Incentive Plan. NOTICE OF GRANT OF PSU AWARD NeoGenomics, Inc. 2023 Equity Incentive Plan FOR GOOD AND VALUABLE CONSIDERATION, NeoGenomics, Inc. (the “Company”) hereby grants, pursuant to the provisions of the NeoGenomics, Inc. 2023 Equity Incentive Plan (the “Plan”), to the Grantee designated in this Notice of Grant of PSU Award (the “Notice”), the number of performance-based RSUs (“PSUs”) set forth in this Noti |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2024 NEOGENOMICS, INC. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2024 NEOGENOMICS, INC. |
|
| February 23, 2024 |
Form of PSU Agreement under the NeoGenomics, Inc. 2023 Equity Incentive Plan NOTICE OF GRANT OF PSU AWARD NeoGenomics, Inc. 2023 Equity Incentive Plan FOR GOOD AND VALUABLE CONSIDERATION, NeoGenomics, Inc. (the “Company”) hereby grants, pursuant to the provisions of the NeoGenomics, Inc. 2023 Equity Incentive Plan (the “Plan”), to the Grantee designated in this Notice of Grant of PSU Award (the “Notice”), the number of performance-based RSUs (“PSUs”) set forth in this Noti |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 20, 2024 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 res |
|
| February 20, 2024 |
Executive Officer Compensation Clawback Policy EXHIBIT 97.1 NEOGENOMICS, INC. NASDAQ RULE 5608 EXECUTIVE OFFICER COMPENSATION CLAWBACK POLICY EFFECTIVE December 1, 2023 1.Policy Purpose. The purpose of this NeoGenomics, Inc. Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy (this “Policy”) is to enable NeoGenomics, Inc. and its subsidiaries and affiliates (the “Company”) to recover Erroneously Awarded Compensation in the event th |
|
| February 20, 2024 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, a UK limited company Inivata, Inc., a Delaware corporation Minuet Diagnostics, Inc., a Delaware corpor |
|
| February 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 20, 2024 NEOGENOMICS, INC. |
|
| February 13, 2024 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: NeoGenomics Inc Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 9, 2024 |
NEO / NeoGenomics, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INC Passive Investment SC 13G/A 1 neoa120924.htm BROWN ADVISORY INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeoGenomics, Inc. (Name of Issuer) (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 NEOGENOMICS, INC. |
|
| November 6, 2023 |
NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Exhibit 99.1 NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022. Third Quarter 2023 Highlights Q3 202 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 8, 2023 |
NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Exhibit 99.1 NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022. Highlights •Consolidated revenue increased 18 |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2023 NEOGENOMICS, INC. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2023 NEOGENOMICS, INC. |
|
| June 29, 2023 |
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors Exhibit 99.1 NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new indep |
|
| June 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 S-8 1 s-8june2023.htm S-8 As filed with the Securities and Exchange Commission on June 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeoGenomics, Inc. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organi |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 NEOGENOMICS, INC. |
|
| May 17, 2023 |
Form of PSU Agreement under the NeoGenomics, Inc. Amended and Restated Equity Incentive Plan. Exhibit 10.1 PERFORMANCE STOCK UNIT AWARD AGREEMENT NEOGENOMICS, INC. AMENDED AND RESTATED EQUITY INCENTIVE PLAN NeoGenomics, Inc. (the “Company”) grants to the Grantee named below (“you”) the number of performance stock units (“PSUs”) set forth below (the “Award”) under the Company’s Amended and Restated Equity Incentive Plan (the “Plan”). The PSUs shall be considered RSUs for purposes of the Pla |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 NEOGENOMICS, INC. |
|
| May 17, 2023 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”) and is effective as of May 12, 2023 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement by |
|
| May 9, 2023 |
Offer Letter dated March 27, 2023 between NeoGenomics Laboratories and Greg Aunan. exhibit101-offerletterda |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 8, 2023 |
NeoGenomics Reports First Quarter 2023 Results First Quarter Revenue Increased 17% to $137 Million Exhibit 99.1 NeoGenomics Reports First Quarter 2023 Results First Quarter Revenue Increased 17% to $137 Million Fort Myers, Florida (May 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023. Highlights •C |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 NEOGENOMICS, INC. |
|
| April 7, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) |
|
| April 7, 2023 |
Table of Contents UNITE D STATE S SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2023 NEOGENOMICS, INC. |
|
| April 4, 2023 |
neoinvestordaymasterxsl Safe Harbor Disclosure This presentation has been prepared by NeoGenomics, Inc. |
|
| February 24, 2023 |
Employment Agreement, dated November 2, 2022 by and between NeoGenomics, Inc. and Warren Stone Exhibit 10.18 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of November 2, 2022 by and between NeoGenomics, Inc. (the “Company”) and Warren Stone (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company desir |
|
| February 24, 2023 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, UK Limited Company Inivata, Inc., Delaware Corporation Minuet Diagnostics, Inc., a Delaware corporatio |
|
| February 24, 2023 |
Employment Agreement, dated November 14, 2022, by and between NeoGenomics, Inc. and Melody Harris Exhibit 10.19 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of November 14, 2022 by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company des |
|
| February 24, 2023 |
Exhibit 10.23 December 20, 2022 William Bonello Dear Bill: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end, effective as of December 31, 2022, (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in this Agreement will have t |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2023 NEOGENOMICS, INC. |
|
| February 23, 2023 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2022 Results Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million Fort Myers, Florida, (February 23, 2023) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2022 resu |
|
| February 10, 2023 |
NEO / NeoGenomics, Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. |
|
| February 9, 2023 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| February 9, 2023 |
NEO / NeoGenomics, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NeoGenomics, Inc. (Name of Issuer) (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) |
|
| February 6, 2023 |
NEO / NeoGenomics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NEOGENOMICS, INC (Name of Issuer) Common Stock (Title of Class of Securities) 64049M209 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2023 NEOGENOMICS, INC. |
|
| December 6, 2022 |
Employment Agreement of Jeffrey S. Sherman, dated December 5, 2022 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2022 by and between NeoGenomics, Inc. (the “Company”) and Jeffrey S. Sherman (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; and WHEREAS, the Company desires |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2022 NEOGENOMICS, INC. |
|
| December 6, 2022 |
Exhibit 99.1 NeoGenomics Announces Chief Financial Officer Transition Jeffrey S. Sherman Appointed Chief Financial Officer FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that Jeffrey S. Sherman will join the company as Chief Financial Officer, effective December 7, 2022. M |
|
| December 5, 2022 |
Exhibit 99.2 NEOGENOMICS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Jeff Sherman (the ?Participant?) as of December 5, 2022. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant a Non-Qualified Stock Option to purchase sha |
|
| December 5, 2022 |
Exhibit 99.1 NEOGENOMICS, INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Jeff Sherman (the ?Participant?) as of December 5, 2022. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant shares of the Company?s Common Stock |
|
| December 5, 2022 |
EX-FILING FEES 2 exhibit107filingfeedecembe.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price per Share (3) Maximum Aggregate Offering Price Fe |
|
| December 5, 2022 |
As filed with the Securities and Exchange Commission on December 5, 2022 As filed with the Securities and Exchange Commission on December 5, 2022 Registration No. |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2022 NEOGENOMICS, INC. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2022 NEOGENOMICS, INC. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 8, 2022 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered into by and between NeoGenomics, Inc. (the ?Company?) and Christopher Smith (the ?Executive?) and is effective as of August 15, 2022 (the ?Effective Date?). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreem |
|
| November 8, 2022 |
Retention Agreement, dated October 15, 2022, by and between NeoGenomics, Inc. and Cynthia Dieter Exhibit 10.1 October 19, 2022 Cindy Dieter Dear Cindy, To incentivize you to remain with and committed to the success of the Company, we are pleased to offer you a special retention bonus (the ?Retention Bonus?), subject to the terms and conditions of this letter. You will be eligible to receive a cash bonus in a total amount equal to $150,000 (less applicable withholdings and deductions). The bon |
|
| November 8, 2022 |
NeoGenomics Reports Third Quarter 2022 Results Third Quarter Revenue Increased 6% to $129 Million Exhibit 99.1 NeoGenomics Reports Third Quarter 2022 Results Third Quarter Revenue Increased 6% to $129 Million Fort Myers, Florida (November 8, 2022) - NeoGenomics, Inc. (NASDAQ: NEO) (the ?Company?), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its third-quarter results for the period ended September 30, 2022. Highl |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2022 NEOGENOMICS, INC. |
|
| November 7, 2022 |
Exhibit 99.1 NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors FT. MYERS, FL, NOVEMBER 7, 2022 ? NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez ? a veteran leader in medical devices and health care services ? to serve on its Board of Directors, effective |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2022 NEOGENOMICS, INC. |
|
| August 12, 2022 |
Exhibit 99.2 NEOGENOMICS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Christopher Smith (the ?Participant?) as of [DATE]. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant a Non-Qualified Stock Option to purchase shares o |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2022 NEOGENOMICS, INC. |
|
| August 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| August 12, 2022 |
Exhibit 99.1 NEOGENOMICS, INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Christopher Smith (the ?Participant?) as of [DATE]. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant shares of the Company?s Common Stock to P |
|
| August 12, 2022 |
As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 9, 2022 |
NeoGenomics Reports Revenue of $125 Million in the Second Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $125 Million in the Second Quarter Second-Quarter 2022 Results and Highlights ?Consolidated revenue increased 3% to $125 million ?Clinical Services revenue increased 4% to $106 million ?Pharma Services revenue decreased 4% to $19 million ?Chris Smith appointed CEO effective August 15, 2022 Fort Myers, Florida (August 9, 2022) - NeoGenomics, Inc. (NASDAQ: |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2022 NEOGENOMICS, INC. |
|
| July 21, 2022 |
Exhibit 99.1 NeoGenomics Announces Chief Executive Officer Appointment Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board Ft. Myers, Florida ? July 21, 2022 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing and global contract research services, today announced that industry veteran Chris Smith has bee |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2022 NEOGENOMICS, INC. |
|
| July 21, 2022 |
Employment Agreement, executed July 20, 2022, by and between NeoGenomics, Inc. and Christopher Smith Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of August 15, 2022 by and between NeoGenomics, Inc. (the ?Company?) and Christopher Smith (the ?Executive?). WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; and WHEREAS, the Company desires t |
|
| July 18, 2022 |
Exhibit 10.1 WITHOUT PREJUDICE/SUBJECT TO CONTRACT DATED July 11, 2022 INIVATA LIMITED (1) and CLIVE MORRIS (2) SETTLEMENT AGREEMENT 1 PARTIES: (1)Inivata Limited, a company incorporated in England & Wales, whose registered office is at The Glenn Berge Building, Babraham, Cambridge, England, CB22 3FH (the "Employer"); and (2)Clive Morris of [***] ("you"). BACKGROUND: (A)You are employed by the Emp |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 NEOGENOMICS, INC. |
|
| June 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 1 s-8june2022.htm S-8 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organi |
|
| May 16, 2022 |
NeoGenomics Appoints Lynn Tetrault Interim CEO Exhibit 99.1 NeoGenomics Appoints Lynn Tetrault Interim CEO Ft. Myers, Florida ? May 16, 2022 - NeoGenomics, Inc. (NASDAQ: NEO) (the ?Company?), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim |
|
| May 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 NEOGENOMICS, INC. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 NEOGENOMICS, INC. |
|
| May 11, 2022 |
Exhibit 99.1 NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary Ft. Myers, Florida ? May 9, 2022 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chie |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 9, 2022 |
Exhibit 10.2 April 25, 2022 Lynn Tetrault [***] Dear Lynn, This letter agreement (this ?Agreement?) confirms the terms and conditions of your role as Executive Chair and Principal Executive Officer of NeoGenomics, Inc. (the ?Company?), effective as of April 19, 2022 (except as otherwise provided herein). At such time as a new Chief Executive Officer of the Company commences employment with the Com |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2022 NEOGENOMICS, INC. |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 NEOGENOMICS, INC. |
|
| April 27, 2022 |
NeoGenomics Reports Revenue of $117 Million in the First Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $117 Million in the First Quarter First-Quarter 2022 Results ?Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% ?Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services revenue increased 4% ?Pharma Services revenue |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2022 NEOGENOMICS, INC. |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14 |
|
| April 14, 2022 |
NeoGenomics Laboratories ? II Transforming Patient Care 2021 ANNUAL REPORT I ? NeoGenomics Laboratories NeoGenomics Laboratories is a speciali d oncolo eference laboratory providing the latest technologies, testing, partnership opportunities, and interactive education to o logy and pathology communities. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2022 NEOGENOMICS, INC. |
|
| March 28, 2022 |
Separation Agreement, dated as of March 28, 2022, by and between NeoGenomics, Inc. and Mark Mallon Exhibit 10.1 March 28, 2022 Mark Mallon Dear Mark: As we have discussed, your employment with NeoGenomics, Inc. (the ?Company?) is coming to an end, effective as of March 28, 2022 (the ?Separation Date?). The purpose of this letter agreement (this ?Agreement?) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in this Agreement will have the respectiv |
|
| March 28, 2022 |
Exhibit 99.1 NeoGenomics Announces CEO Departure and Initiates CEO Search Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance Ft. Myers, Florida?March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the ?Company?), a leading provider of cancer-focused genetic testing services and global oncology contract research serv |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2022 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-35756 74-2897368 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2022 NEOGENOMICS, INC. |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 25, 2022 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, UK Limited Company Inivata, Inc., Delaware Corporation Minuet Diagnostics, Inc., a Delaware corporatio |
|
| February 25, 2022 |
Form of Executive Employment Agreement between NeoGenomics, Inc. and each of its executive officers Exhibit 10.11 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of [?] by and between NeoGenomics, Inc. (the ?Company?) and [?] (the ?Executive?). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company desires to [continue to]1 e |
|
| February 23, 2022 |
Exhibit 99.1 NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021 Recent Highlights: ?Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% ?Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue in |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2022 NEOGENOMICS, INC. |
|
| February 10, 2022 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Ru |
|
| February 4, 2022 |
NEO / NeoGenomics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEOGENOMICS, INC (Name of Issuer) Common Stock (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2022 NEOGENOMICS, INC. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 NEOGENOMICS, INC. |
|
| November 4, 2021 |
Employment Agreement between NeoGenomics, Inc. and Halley Gilbert dated August 9, 2021. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 9th day of August, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and Halley Gilbert (?Executive?), an individual |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 NEOGENOMICS, INC. |
|
| November 4, 2021 |
NeoGenomics Reports Revenue of $121 Million in the Third Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $121 Million in the Third Quarter Third-Quarter 2021 Results and Highlights: ?Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million ?Consolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consolidated revenue increased 12% when excludin |
|
| October 12, 2021 |
EX-99.1 2 a99-1pressrelease.htm EX-99.1 Exhibit 99.1 NeoGenomics Announces Board of Directors’ Transition Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year Ft. Myers, Florida – October 12, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2021 NEOGENOMICS, INC. |
|
| September 1, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| September 1, 2021 |
NEOGENOMICS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 NEOGENOMICS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On May 4, 2021, NeoGenomics Laboratories, Inc. (?NeoGenomics Laboratories?), a subsidiary of NeoGenomics, Inc. (?NeoGenomics? or the ?Company?), entered into a Share Purchase Agreement, by and between NeoGenomics Laboratories and Inivata Limited, a private limited company incorporated in England and Wal |
|
| September 1, 2021 |
As filed with the Securities and Exchange Commission on September 1, 2021 As filed with the Securities and Exchange Commission on September 1, 2021 Registration No. |
|
| September 1, 2021 |
Exhibit 99.1 INIVATA LIMITED Consolidated financial statements for the years ended 31 December 2020 and 2019 Registered number: 09144647 INIVATA LIMITED Consolidated financial statements for the years ended 31 December 2020 and 2019 Registered number: 09144647 Page(s) Report of Independent Auditors 3 Consolidated statements of comprehensive income 4 Consolidated balance sheets 5 Consolidated state |
|
| August 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 NEOGENOMICS, INC. |
|
| August 10, 2021 |
NeoGenomics Investor Presentation August 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or juris |
|
| August 9, 2021 |
Employment Agreement between NeoGenomics, Inc. and George Cardoza dated July 5, 2021. Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 5th day of July, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and George Cardoza (?Executive?), an individual wh |
|
| August 9, 2021 |
Services Agreement between Inivata Limited and Clive Morris dated June 18, 2021. Exhibit 10.4 CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DATED 2021 INIVATA LIMITED (1) and CLIVE MORRIS (2) SERVICE AGREEMENT THIS AGREEMENT IS DATED 2021 PARTIES: (1)Inivata Limited whose registered office is at The Glenn Berge Building, Babraham, Camb |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 9, 2021 |
Employment Agreement between NeoGenomics, Inc. and Gina Wallar dated July 5, 2021. Exhibit 10.6 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 5th day of July, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #9, Fort Myers, Florida 33913 and Gina Wallar (?Executive?), an individual who r |
|
| August 6, 2021 |
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter Exhibit 99.1 NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter Second-Quarter 2021 Results and Highlights: ?Consolidated revenue increased 40% to $122 million ?Clinical Services revenue increased 37% to $101 million ?Pharma Services revenue increased 55% to $20 million ?Completed the acquisitions of Trapelo Health in April and Inivata Limited in June Fort Myers, Florida |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 NEOGENOMICS, INC. |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 5, 2021 NEOGENOMICS, INC. |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2021 NEOGENOMICS, INC. |
|
| June 24, 2021 |
Exhibit 99.1 NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market Ft. Myers, Florida ? June 18, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and glob |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2021 NEOGENOMICS, INC. |
|
| June 2, 2021 |
As filed with the Securities and Exchange Commission on June 2, 2021 As filed with the Securities and Exchange Commission on June 2, 2021 Registration No. |
|
| June 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2021 NEOGENOMICS, INC. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2021 NEOGENOMICS, INC. |
|
| May 6, 2021 |
NeoGenomics Investor Presentation May 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdic |
|
| May 5, 2021 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of May 4, 2021 by and among NeoGenomics, Inc., a Nevada corporation (the ?Company?), and the several Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are execu |
|
| May 5, 2021 |
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter Exhibit 99.1 NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter First-Quarter 2021 Results and Highlights: ?Consolidated revenue increased 9% to $116 million ?Clinical Services revenue increased 4% to $96 million ?Pharma Services revenue increased 46% to $19 million ?Completed the acquisition of Trapelo Health in April Fort Myers, Florida (May 5, 2021) - NeoGenomics, Inc. ( |
|
| May 5, 2021 |
Exhibit 99.1 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market ?NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million ?Completes $200 million strategic financing with leading oncol |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of May 4, 2021 by and among NeoGenomics, Inc., a Nevada corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 4, 2021 (the ?Purchase Agreement?). Capi |
|
| May 5, 2021 |
Exhibit 99.1 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market ?NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million ?Completes $200 million strategic financing with leading oncol |
|
| May 5, 2021 |
Exhibit 2.1 Execution Version ? Exercise Notice Dated May 4, 2021 between THE INITIAL SELLERS and NEOGENOMICS LABORATORIES, INC. as Buyer and INIVATA LIMITED as the Company SHARE PURCHASE AGREEMENT RELATING TO THE SALE AND PURCHASE OF THE ENTIRE ISSUED SHARE CAPITAL OF INIVATA LIMITED TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATIONS 2 2. SALE OF SHARES 2 3. CONSIDERATION 2 4. ALLOCATION S |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e) |
|
| April 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14 |
|
| April 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
2020 | Exhibit 99.1 Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world?s leading cancer testing and information company. OUR VALUES Quality, Integrity, Accountability, Teamwork, and Innovation Becoming the World?s Leading |
|
| April 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2021 NEOGENOMICS, INC. |
|
| April 7, 2021 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-231608 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.001 per share 597,712 $49.375 $29,512,030 $3,220 (1) Pursuant to Rule 416(a) u |
|
| March 24, 2021 |
NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Exhibit 99.1 NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Ft. Myers, Florida ? March 24, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Intervention Insights, Inc. d/b/a Trapelo Health, an Informa |
|
| March 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2021 NEOGENOMICS, INC. |
|
| March 1, 2021 |
Employment Agreement between NeoGenomics, Inc. and Mark Mallon dated February 23, 2021 Exhibit 10.1 Execution Copy EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 23rd day of February, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and Mark Mallon (?Executive?), |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2021 NEOGENOMICS, INC. |
|
| March 1, 2021 |
NeoGenomics Announces CEO Succession Mark Mallon named CEO effective April 2021; Douglas M. |
|
| February 25, 2021 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. NeoGenomics Laboratories, Inc., a Florida corporation NeoGenomics Bioinformatics, Inc., a Florida corporation NeoGenomics Foundation, Inc., a Florida Corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Minuet Diagnostics, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Clarie |
|
| February 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2021 NEOGENOMICS, INC. |
|
| February 25, 2021 |
NeoGenomics Investor Presentation January 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or juri |
|
| February 25, 2021 |
Offer Letter dated May 8, 2020 between Ms. Cynthia J. (Cindy) Dieter and NeoGenomics, Inc. Exhibit 10.15 Exhibit 10.15 /s/ Heather Carter Exhibit 10.15 /s/ Cindy Dieter 05/08/2020 Exhibit 10.15 |
|
| February 25, 2021 |
Employment Agreement dated February 10, 2020 between Mr. Douglas Brown and NeoGenomics, Inc. Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 /s/ Douglas M. VanOort /s/ Douglas Brown Exhibit 10.14 Exhibit 10.14 |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2021 NEOGENOMICS, INC. |
|
| February 24, 2021 |
NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter Exhibit 99.1 NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter Fourth-Quarter 2020 Results and Highlights: •Consolidated revenue increased 18% to $126 million •Clinical Services revenue increased 14% to $107 million •Pharma Services revenue increased 43% to $19 million •Pharma Services backlog increased 60% to $209 million Ft. Myers, Florida - February 24, 2021 - NeoGeno |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2021 NEOGENOMICS, INC. |
|
| January 11, 2021 |
Form of Capped Call Confirmation. Exhibit 10.1 [GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000 Opening Transaction]1 [Bank of America, N.A. One Bryant Park New York, NY 10036]2 [Morgan Stanley & Co. LLC 1585 Broadway, 4th Floor New York, NY 10036]3 [], 2021 To: NeoGenomics, Inc. 12701 Commonwealth Drive, Suite 9 Fort Myers, FL 33913 Attention: Kathryn McKenzie, Chief Financial Officer |
|
| January 11, 2021 |
irpresentation01112021 Exhibit 99.1 Our Common Purpose Our Values Our Vision FY 2019 Key Figures Revenue: Revenue Growth: Clinical Test Volume: Gross Margin: Adjusted EBITDA: • • • • • • *Excluding non-core COVID-19 PCR Testing • • • • • • • • • • NOTE: 13 locations across 3 continents Demographics Precision Medicine & Drug Development Upside Potential: Emerging Opportunities 22.2 31% increase by |
|
| January 11, 2021 |
Exhibit 1.2 $300,000,000 NeoGenomics, Inc. (a Nevada corporation) 0.25% Convertible Senior Notes due 2028 UNDERWRITING AGREEMENT January 6, 2021 BofA Securities, Inc. One Bryant Park New York, New York 10036 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 as Representatives of the several Underwriters Ladies and Gentl |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2021 NEOGENOMICS, INC. |
|
| January 11, 2021 |
Exhibit 4.1 NEOGENOMICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of January 11, 2021 0.25% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 Section 1.03. Incorporation by Reference of Trust Indenture Act 13 Section 1.04. Conflicts with the Trust Indenture Act 13 ARTICLE |
|
| January 11, 2021 |
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Exhibit 99.1 NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Fort Myers, Florida (January 6, 2021) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced the pricing of concurrent underwritten public offerings of (a) 4,081,632 sha |
|
| January 11, 2021 |
Exhibit 1.1 NeoGenomics, Inc. (a Nevada corporation) 4,081,632 Shares of Common Stock UNDERWRITING AGREEMENT January 6, 2021 BofA Securities, Inc. One Bryant Park New York, New York 10036 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 as Representatives of the several Underwriters Ladies and Gentlemen: NeoGenomics, I |
|
| January 8, 2021 |
CALCULATION OF REGISTRATION FEE CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be registered Proposed maximum offering price per unit Proposed maximum aggregate offering price Amount of registration fee 0. |
|
| January 8, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231608 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be registered Amount of Registration Fee(1) Common Stock, par value $0.001 per share $229,999,924(2) $25,093.00 •Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in con |
|
| January 7, 2021 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| January 5, 2021 |
neoinvestorpowerpointfin NeoGenomics Investor Presentation January 2021 1 Exhibit 99. |
|
| January 5, 2021 |
Form of Indenture (including form of note) Exhibit 4.1 NEOGENOMICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of January [ ], 2021 [ ]% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 Section 1.03. Incorporation by Reference of Trust Indenture Act 13 Section 1.04. Conflicts with the Trust Indenture Act 13 ARTICLE |
|
| January 5, 2021 |
Form T-1 Statement of Eligibility of Trustee under the Trust Indenture Act of 1939, as amended EX-25.1 7 exhibit251formt-12021.htm EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its c |
|
| January 5, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2021 NEOGENOMICS, INC. |
|
| January 5, 2021 |
Subject to completion, dated January 5, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-231608 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to com |
|
| January 5, 2021 |
As filed with the Securities and Exchange Commission on January 5, 2021 Registration No. |
|
| October 29, 2020 |
boardappointmentletter-k Exhibit 10.2 NEO GENOMICS August 11, 2020 Michael A. Kelly Re: NeoGenomics, Inc. Board and Audit Committee Appointments Dear Michael: On behalf of the entire Board of Directors (the "Board") of NeoGenomics, Inc., a Nevada corporation (the "Company"), it is my sincere pleasure to provide this written confirmation of your appointment to the Company's Board of Directors and A |
|
| October 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2020 NEOGENOMICS, INC. |
|
| October 29, 2020 |
irpresentation2020q3earn Exhibit 99.1 INVESTOR PRESENTATION October 2020 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any stat |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| October 29, 2020 |
boardappointmentletter-s Exhibit 10.1 August 11, 2020 Rachel A. Stahler Re: NeoGenomics, Inc. Board, Audit and NCG Committee Appointments Dear Rachel: On behalf of the entire Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), it is my sincere pleasure to provide this written confirmation of your appointment to the Company’s Board of Directors, Audit and Fi |
|
| October 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2020 NEOGENOMICS, INC. |
|
| October 27, 2020 |
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter Exhibit 99.1 NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter Third-Quarter 2020 Results and Highlights: •Consolidated revenue increased 20% to $125 million •Clinical Services revenue increased 17% to $109 million •Pharma Services revenue increased 38% to $17 million •Pharma Services backlog increased 57% to $185 million Fort Myers, Florida (October 27, 2020) - |
|
| July 31, 2020 |
irpresentationjuly2020q2 INVESTOR PRESENTATION July 2020 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. |
|
| July 31, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2020 NEOGENOMICS, INC. |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| July 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2020 NEOGENOMICS, INC. |
|
| July 28, 2020 |
NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic Exhibit 99.1 NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic Second-Quarter 2020 Results and Highlights: •Consolidated revenue decreased 14% to $87 million •Clinical Services revenue decreased 17% to $74 million •Pharma Services revenue increased 3% to $13 million •Pharma Services backlog increased 63% to $173 million •Financial position strengthened with $3 |
|
| July 20, 2020 |
NeoGenomics Announces Board Appointments Exhibit 99.1 NeoGenomics Announces Board Appointments Ft. Myers, Florida – July 20, 2020 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today changes in the composition and certain roles of its Board of Directors. Rachel A. Stahler joined our Board of Directors on May 28, 2020 and will serve as a member of the Audit Committee and the Nom |
|
| July 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2020 NEOGENOMICS, INC. |
|
| June 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2020 NEOGENOMICS, INC. |
